Department of Nephrology, First Medical Center of Chinese People's Liberation Army General Hospital, Nephrology Institute of the Chinese People's Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing 100853, China.
Medical School of Chinese People's Liberation Army, Beijing 100853, China.
Int J Mol Sci. 2023 Sep 1;24(17):13560. doi: 10.3390/ijms241713560.
Diabetic nephropathy (DN), as the one of most common complications of diabetes, is generally diagnosed based on a longstanding duration, albuminuria, and decreased kidney function. Some patients with the comorbidities of diabetes and other primary renal diseases have similar clinical features to DN, which is defined as non-diabetic renal disease (NDRD). It is necessary to distinguish between DN and NDRD, considering they differ in their pathological characteristics, treatment regimes, and prognosis. Renal biopsy provides a gold standard; however, it is difficult for this to be conducted in all patients. Therefore, it is necessary to discover non-invasive biomarkers that can distinguish between DN and NDRD. In this research, the urinary exosomes were isolated from the midstream morning urine based on ultracentrifugation combined with 0.22 μm membrane filtration. Data-independent acquisition-based quantitative proteomics were used to define the proteome profile of urinary exosomes from DN (n = 12) and NDRD (n = 15) patients diagnosed with renal biopsy and Type 2 diabetes mellitus (T2DM) patients without renal damage (n = 9), as well as healthy people (n = 12). In each sample, 3372 ± 722.1 proteins were identified on average. We isolated 371 urinary exosome proteins that were significantly and differentially expressed between DN and NDRD patients, and bioinformatic analysis revealed them to be mainly enriched in the immune and metabolic pathways. The use of least absolute shrinkage and selection operator (LASSO) logistic regression further identified phytanoyl-CoA dioxygenase domain containing 1 (PHYHD1) as the differential diagnostic biomarker, the efficacy of which was verified with another cohort including eight DN patients, five NDRD patients, seven T2DM patients, and nine healthy people. Additionally, a concentration above 1.203 μg/L was established for DN based on the ELISA method. Furthermore, of the 19 significantly different expressed urinary exosome proteins selected by using the protein-protein interaction network and LASSO logistic regression, 13 of them were significantly related to clinical indicators that could reflect the level of renal function and hyperglycemic management.
糖尿病肾病(DN)是糖尿病最常见的并发症之一,通常基于长期病程、白蛋白尿和肾功能下降来诊断。一些患有糖尿病和其他原发性肾脏疾病合并症的患者具有与 DN 相似的临床特征,被定义为非糖尿病性肾脏疾病(NDRD)。有必要区分 DN 和 NDRD,因为它们在病理特征、治疗方案和预后方面存在差异。肾活检提供了金标准;然而,并非所有患者都能进行这种检查。因此,有必要发现能够区分 DN 和 NDRD 的非侵入性生物标志物。在这项研究中,基于超速离心结合 0.22μm 膜过滤从中段晨尿中分离尿外泌体。基于数据独立获取的定量蛋白质组学用于定义经肾活检诊断的 DN(n=12)和 NDRD(n=15)患者以及无肾损伤的 2 型糖尿病(T2DM)患者(n=9)和健康人(n=12)的尿外泌体的蛋白质组谱。在每个样本中,平均鉴定出 3372±722.1 种蛋白质。我们分离出 371 种在 DN 和 NDRD 患者之间差异表达的尿外泌体蛋白,生物信息学分析表明它们主要富集在免疫和代谢途径中。使用最小绝对收缩和选择算子(LASSO)逻辑回归进一步确定植烷酰辅酶 A 双加氧酶结构域包含蛋白 1(PHYHD1)为差异诊断生物标志物,并用包括 8 例 DN 患者、5 例 NDRD 患者、7 例 T2DM 患者和 9 例健康人的另一个队列验证了其疗效。此外,还基于 ELISA 方法建立了基于浓度大于 1.203μg/L 来诊断 DN。此外,在使用蛋白质-蛋白质相互作用网络和 LASSO 逻辑回归选择的 19 种显著差异表达的尿外泌体蛋白中,有 13 种与能够反映肾功能和高血糖管理水平的临床指标显著相关。